EGFR and non-small cell lung carcinoma: The objective of this study is to comprehensively analyze the cost-effectiveness of the 12 first-line treatments including 6 EGFR-TKIs (osimertinib, dacomitinib, afatinib, erlotinib, gefitinib, icotinib), 4 combination treatments (afatinib plus cetuximab, erlotinib plus bevacizumab, gefitinib plus PbCT, and gefitinib plus pemetrexed) and 2 chemotherapies (PbCT, pemetrexed free chemotherapy (PfCT)) for patients with advanced EGFR mutated NSCLC.